Tag: inhibitors

JAK inhibitors associated with aggressive lymphoma

Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. They also speculate that screening for a preexisting B-cell clone before starting therapy may help prevent this side effect and potentially save lives, according to a study published online

Outcomes-based pricing doesn’t cut costs of PCSK9 inhibitors

(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine. Dhruv S. Kazi, M.D., from the University of California in San Francisco, and colleagues examined the effect of outcomes-based pricing on the cost-effectiveness of PCSK9